Page 322 - Read Online

Mokhamatam et al. J Cancer Metastasis Treat 2020;6:28 I http://dx.doi.org/10.20517/2394-4722.2020.38 Page 9 of 9

68. Nakamura T, Sato T. Advancing intestinal organoid technology toward regenerative medicine. Cell Mol Gastroenterol Hepatol 2018;5:51-
60.
69. Sato T, Vries RG, Snippert HJ, van de Wetering M, Barker N, et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a
mesenchymal niche. Nature 2009;459:262-5.
70. Zhang J, Cai H, Sun L, Zhan P, Chen M, et al. LGR5, a novel functional glioma stem cell marker, promotes EMT by activating the Wnt/
β-catenin pathway and predicts poor survival of glioma patients. J Exp Clin Cancer Res 2018;37:225.
71. Method of the Year 2017: Organoids. Nat Methods 2018;15:1.
72. Fan H, Demirci U, Chen P. Emerging organoid models: leaping forward in cancer research. J Hematol Oncol 2019;12:142.
73. van de Wetering M, Francies HE, Francis JM, Bounova G, Iorio F, et al. Prospective derivation of a living organoid biobank of colorectal
cancer patients. Cell 2015;161:933-45.
74. Hubert CG, Rivera M, Spangler LC, Wu Q, Mack SC, et al. A three-dimensional organoid culture system derived from human
glioblastomas recapitulates the hypoxic gradients and cancer stem cell heterogeneity of tumors found in vivo. Cancer Res 2016;76:2465-
77.
75. Hahn S, Nam MO, Noh JH, Lee DH, Han HW, et al. Organoid-based epithelial to mesenchymal transition (OEMT) model: from an
intestinal fibrosis perspective. Sci Rep 2017;7:2435.
76. Clevers HC. Organoids: avatars for personalized medicine. Keio J Med 2019;68:95.
77. Pauli C, Hopkins BD, Prandi D, Shaw R, Fedrizzi T, et al. Personalized in vitro and in vivo cancer models to guide precision medicine.
Cancer Discov 2017;7:462-77.